James E. Fickenscher - Jan 26, 2022 Form 4 Insider Report for Zynerba Pharmaceuticals, Inc. (ZYNE)

Role: Chief Financial Officer
Signature: /s/ Suzanne M. Hanlon, Attorney-in-Fact
Stock symbol: ZYNE
Transactions as of: Jan 26, 2022
Transactions value $: $0
Form type: 4
Date filed: 1/28/2022, 03:18 PM
Next filing: Jul 20, 2022

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	ZYNE	Common Stock	Award	$0	+85K	+116.89%	$0.00	158K	Jan 26, 2022	Direct	F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	ZYNE	Stock Option (right to buy)	Award	$0	+125K		$0.00	125K	Jan 26, 2022	Common Stock	125K	$2.41	Direct	F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	The restricted stock award will fully vest on January 26, 2024, subject to continued employment with the Company through the applicable vesting date.
F2	The stock option vests 25% on the first anniversary of the date of the grant, with the remainder vesting in 12 equal quarterly installments thereafter, subject to continued employment with the Company through the applicable vesting date.